Efficacy and Safety of Datopotamab Deruxtecan in Patients with Pretreated Advanced/Metastatic NSCLC with Actionable Genomic Alterations By Ogkologos - January 27, 2025 461 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TROPION-Lung05 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR ESMO AI & Digital Oncology Congress 2025 Closed in Berlin under... November 17, 2025 Sacituzumab Govitecan Demonstrates Significant Improvement in Survival in Heavily Pretreated, Locally... September 5, 2022 EMA Recommends Granting a Marketing Authorisation for Zanubrutinib for the Treatment... October 21, 2021 ESMO Highlights Key Issues for Patients with Cancer and Their Carers... May 27, 2025 Load more HOT NEWS How NatWest Group are making a difference this Giving Tuesday COVID-19 Vaccines: Considerations for Special Populations Perioperative Durvalumab Plus FLOT Improves OS in Patients with Resectable Gastric... EMA Recommends Granting a Marketing Authorisation for Lisocabtagene Maraleucel
